To study the efficacy and safety of a low dose of MTX combined with a low dose of methylprednisolone (MP) as a first-line therapy in the treatment of acute GVHD (aGVHD) after allogeneic hematopoietic SCT, 32 patients received i.v. MTX at a dose of 10 mg or oral MTX at a dose of 15 mg every 3-7 days (repeated at day 3 after the first dose and then at a weekly interval) combined with a low dose of MP (0.5 mg/kg/day) until a complete or partial response was achieved, or until treatment failure or intolerable side effects occurred. The overall treatment response rate was 81% (26/32 patients) and the response rate at day 28 was 75% (24/32 patients). The response rate for GVHD involving various organs was 88% (23/26) in the skin, 75% (3/4) in the liver and 81% (9/11) in the gut. Grade 3 toxicities occurred in only three patients presenting cytopenias. The estimated survival at 2 years was 77%. From this analysis, MTX in combination with a low dose of MP appears to be a well-tolerated, effective and inexpensive regime when used as a first-line treatment for aGVHD.
Introduction
Acute GVHD (aGVHD) is one of the most common complications after hematopoietic SCT (HSCT), with an incidence of about 30-80%. 1 Przepiorka et al. 2 reported aGVHD, grading 100-day survival rates of 78-90% for grade I, 66-92% for grade II, 29-62% for grade III and 23-25% for grade IV. Once the diagnosis of aGVHD is confirmed, immediate treatment should be administered. The current first-line therapy for aGVHD is methylprednisolone (MP, 1-2 mg/kg/day). 3, 4 McDonald et al. 5, 6 reported on patients who received prednisone (1 mg/kg/ day) for the treatment of intestinal GVHD. The initial treatment response at day 10 was 16 of 29 (55%) and the durable treatment response at day 30 was 12 of 29 (41%). A total of 47 patients undergoing an allogeneic BMT who developed aGVHD received MP (2 mg/kg/day). In these patients, the response rate of aGVHD was 68%, whereas evolution of aGVHD grade III-IV was 17%. 5 However, in addition to profound immunosuppression with associated risks of infection, prolonged exposure to glucocorticoids may contribute to overall morbidity and impairment of quality of life by causing hyperglycemia, hypertension, myopathy, avascular necrosis, osteoporosis and neuropsychological alterations, among other complications. 7, 8 As a cytotoxic and immunosuppressive drug, MTX has been successfully used for the prevention of aGVHD. Our recently published data 9 showed that low doses of MTX can be used as a second-line option to treat different types of GVHD, including aGVHD, chronic GVHD (cGVHD) and post-donor leukocyte infusions GVHD, with response rates of 93, 75 and 100%, respectively. In our recently published study 10 from 86 patients with low-dose MTX as a first-line treatment for cGVHD, high response rates and minimal toxicity was demonstrated, and most of the patients were able to either discontinue or reduce the dose of other immunosuppressive agents such as CsA, MP or mycophenolate mofetil (MMF), which may be beneficial for the recovery of immune function. On the basis of these findings, we hypothesized that MTX combined with low doses of MP (0.5 mg/kg/day) might be used as a first-line therapy for aGVHD. Therefore, we evaluated the efficacy and safety of MTX combined with low-dose MP for the treatment of aGVHD.
Materials and methods

Patients and donors
The study was approved by the institutional review board of the Peking University Institute of Hematology. All included patients were informed about the treatment and signed an informed consent form. Patients with aGVHD after HSCT who had not received drug treatments and whose peripheral blood WBC counts were higher than 1.5 Â 10 9 cells per L were selected. Patients were informed about the risks, benefits and uncertain outcomes associated with the use of MTX, and alternatives were explained.
A total of 32 patients were enrolled from May 2007 to June 2008. The subject characteristics are shown in Table 1 . HLA-A, HLA-B and HLA-DRB1 typing was performed at the allele level using high-resolution techniques. Three siblings and three unrelated donor-recipient pairs were fully HLA-matched. The degree of HLA incompatibility in patients receiving related HLA-mismatched transplants is shown in Table 1 .
Conditioning regimen
Conditioning therapy in matched sibling transplantations consisted of hydroxyurea (80 mg/kg in two doses) on day À10, cytarabine (Ara-C, 2 g/m 2 , i.v) on day À9, Bu (12 mg/kg, p.o., in 12 doses) on days À8 to À6, CY (1. /day) on days À10 and À9, along with antithymocyte globulin (ATG; 2.5 mg/kg/day, i.v., of the Genzyme product, Genzyme, Boston, MA, USA) on days À5 to À2, but otherwise had an identical regimen to the HLAmatched sibling patients. 11, 12 GVHD prophylaxis All transplant recipients received CsA, MMF and shortterm MTX. The dosage of CsA was 2.5 mg/kg/day i.v. from day À9 until bowel function returned to normal. At that point, the patient was switched to oral CsA. MMF was administered orally, 0.5 g every 12 h, from day À9. The dosage of MTX was 15 mg/m 2 , administered i.v. on day þ 1, followed by 10 mg/m 2 on days 3 and 6 after matched sibling transplantation or days 3, 6 and 11 after mismatched/haploidentical or unrelated transplantation. 13 Whole-blood CsA concentration was monitored weekly using fluorescence polarization immunoassays, and the dosage was adjusted to a blood concentration of 150-250 ng/mL. If no evidence of GVHD was found by days 40-50, the CsA dosage was reduced gradually and discontinued around day 180. If GVHD was diagno0sed, CsA was continued. MMF was discontinued upon neutrophil engraftment after matched sibling HSCTs, or on day 30 after unrelated HSCTs, whereas in HLA-mismatched/haploidentical patients, MMF was tapered from 1 g/day to 0.5 g/day on day 30 and was discontinued on day 60.
Staging of aGVHD and definitions
Before initiation of the treatment, patients underwent a thorough evaluation to ascertain the severity and extent of their GVHD, including a physical examination, laboratory evaluations and a consultation without the tissue biopsy results. Each organ (skin, liver and gut) was staged I through to IV for aGVHD according to modified criteria based on the schema of Glucksberg et al., 14 and patients were also assigned a grade of aGVHD (I through to IV) based on overall severity. 15 Evolution of GVHD was defined as occurring when the grades at the onset progressed to more severe GVHD.
Drug administration regimens
Patients received i.v. MTX at a dose of 10 mg or oral MTX at a dose of 15 mg, as well as a low dose of MP (0.5 mg/kg/ day). MTX (10 mg/day) was given on days 1, 3, 8 and 15, and once every 7 days afterward; the programmed dose of MP was days 1-5, 0.5 mg/kg/day; days 6-12, 0.25 mg/kg/ day; and days 13-19, 0.125 mg/kg/day, and the dose was reduced by half after 5-7 days until it was stopped. In other words, for most patients weighing about 60 kg, the programmed dose of MP was days 1-5, 30 mg/day; days 6-12, 15 mg/day; days 13-19, 7.5 mg/day; and days 20-26, 3.75 mg/day; with cessation at about day 30 after the initial drug administration. Drug dosage was adjusted according to the hemogram. MTX was administered at a dose of 5 mg i.v. or 10 mg orally if WBC o2 Â 10 9 cells per L or platelet count o50 Â 10 9 cells per L. Otherwise, it was administered at a dose of 10 mg i.v. or 15 mg orally. Patients were scheduled to receive at least two doses (number of MTX administrations) for evaluation of the drug's efficacy. If patients responded and were able to tolerate the toxicity, additional doses were used for consolidation and the scheduled maximal doses were capped at six because of the concern that MTX may affect blood cell counts for aGVHD patients, especially when given soon after transplantation. Pediatric patients received MTX at a dose of 10 mg/m 2 , with a maximum dose of 10 mg per administration. There were three patients under the age of 16 years (3, 7 and 9 years old) with weights of 17, 28 and 70 kg, respectively. Therefore, their MTX doses were 5, 10 and 10 mg per administration.
Second-line treatment
Patients were observed for 3-5 days and switched to the second-line treatment if there was no response to the firstline therapy. Second-line treatment should be added when functional deterioration appeared in any organs after 3 days of treatment, or no symptom amelioration occurred after 5 days of treatment. The second-line treatment selected was Daclizumab (1 mg/kg) on days 1, 4 and 8, and weekly afterward for as long as was clinically indicated. This second-line treatment was given to patients with no response, not including patients who responded to MTX/ MP at first and then flared.
Drug delivery methods
Because the safety and effectiveness of low-dose MTX had been observed and it was determined to be inconvenient for parenteral use, especially in outpatients, we tried oral administration in some patients. Absorption may be limited by severe gut GVHD and for GVHD patients before day 30 after transplantation whose gut function may not return to normal. Therefore, MTX and MP were used i.v. in all inpatients, patients before day 30 after transplantation and patients with gut GVHD. Alternatively, for outpatients, patients post day 30 after transplantation and patients without gut GVHD, drugs were administered orally. Otherwise, the method of administration was determined at each physician's discretion.
Assessment of efficacy
We evaluated the treatment response daily after therapy until maximal response was achieved. Because some patients respond to treatment at first and then flare, we also review the treatment response at day 28 after the start of drug administration. A complete response (CR) was classified as complete disappearance of all clinical signs of skin, liver and/or gut GVHD. A partial response (PR) was said to have occurred if GVHD symptoms in the patient had not completely disappeared, but at least one target organ decreased in grading by at least one stage (rash area reduced by over 25% and diarrhea decreased by 500 mL/ day or more; patients with bilirubin 48 mg per 100 mL showed a decline in bilirubin of 425%, those with 4-8 mg per 100 mL showed a decline of 42 mg per 100 mL and those with 2-4 mg per 100 mL declined to o2 mg per 100 mL), without deterioration in other organs or the emergence of GVHD in other organs. Overall responses included CR and PR. Patients were considered to have no response or treatment failure if GVHD progressed or failed to improve (stable disease) after two administrations of MTX. The manifestation of each organ in aGVHD was estimated as resolution, improvement, stable or progression. When GVHD symptoms completely disappeared, it was called resolution; when there was no change in the extent or severity of the disease it was considered to be stable; and in the event of the worsening of the abovementioned parameters, it was termed 'progression'.
End points of the study Primary end points were response to therapy or evolution of GVHD. Type of response is described above in the 'Assessment of efficacy' section. The secondary end points were incidence of bacterial infections, fungal infections, CMV infections, cGVHD, TRM and leukemia relapse.
Outcome evaluation
Changes in clinical symptoms after treatment were observed, and the time at which the rash disappeared or diminished and abdominal pain and diarrhea improved or healed were recorded. Biochemical parameters, including liver total bilirubin, direct bilirubin, indirect bilirubin, alanine aminotransferase, glutamyl transferase and alkaline phosphatase were monitored. In addition, incidence of infection, cGVHD incidence, relapse rate, survival rate and TRM in patients were documented. Meanwhile, changes in WBC count and drug side effects were evaluated to assess drug safety. The Common Terminology Criteria (CTC) for Adverse Events version 3.0 was used to grade the severity of side effects.
Statistical methods
Data were collected on case report forms by medical record reviews. Numeric variables (mainly involving time or dosages of MTX) were analyzed as categories by considering their value below or above the median of the entire cohort, as indicated in the results section. Laboratory values (complete blood counts, liver function tests and renal function tests) were analyzed with reference to normal ranges and pretreatment baselines. The time that elapsed between the onset of aGVHD and HSCT was defined as the time from HSCT to the onset of any grade of aGVHD. A w 2 -test was used to compare response rates between patients prepared with ATG and those not prepared with ATG. The probability of survival and the time course for aGVHD response were estimated using the method of Kaplan and Meier. Cumulative incidences were estimated for TRM and relapse in order to account for competing risks. The surviving patients were followed up, and the results of the follow-up examinations were analyzed on 1 January 2010. Unless otherwise specified, all the reported P-values were based on two-sided hypothesis tests. The SPSS software package (SPSS Inc., Chicago, IL, USA) was used for data analyses.
Results
Drug use
aGVHD occurred at a median of 32 days (range, 9-90 days) after HSCT in 32 patients. The drugs were administered immediately after aGVHD was diagnosed.
The drugs were administered orally or i.v. in 12 and 20 patients, respectively.
Responses
The overall response rates and CR rates were 81% (26/32 patients) and 72%.(23/32). Among the six nonresponders, evolution of aGVHD grade III occurred in two patients with grade I-II at onset. By day 28 after drug administration, 2 of the 26 responders flared. Therefore, the overall treatment response at day 28 was 24 out of 32 (75%). There was no difference in overall response rates between patients prepared with ATG and those not prepared with ATG (24/ 29 vs 1/3; P ¼ 0.49). Responses in different grades of GVHD (the grades at onset), individual organs involved and the number of involved organs are shown in Table 2 . The time course for aGVHD response is shown in Figure 1 .
Drug dosage
MTX was administered a median of four times (two to six times). The median time to show improvement (o50% improvement, not reaching PR) was 2 days (range, 1-5 days) after application, and the accumulated dose necessary to show improvement was 10 mg (range, 5-20 mg). The median time needed to achieve a maximal response (CR or PR) was 5 days (range, 2-13 days) and the accumulated dose needed to achieve a maximal response was 20 mg (range, 5-40 mg). The median overall dose of MTX was 35 mg (range, 10-60 mg).
Second-line treatment
A total of 6 of 32 (18%) patients with no response to MTX/ MP therapy required daclizumab as a second-line treatment. Daclizumab was effective for all of these six cases after a median of four (two to seven) administrations. By day 28 after drug administration, 2 of the 26 responders flared, one was given the standard dose of MP (2 mg/kg) and the other was given FK506 instead of CsA for treatment. Therefore, 3% of patients required steroid dose-escalation by day 28 after MTX/MP administration. , 56 Â 10 9 and 74 Â 10 9 cells per L before and after MTX administration, respectively. None of the patients required blood-product transfusions or treatment with hematopoietic growth factors. No patient was withdrawn from the study because of hematological side effects and their blood cell counts quickly returned to baseline values after drug withdrawal. Levels of blood glucose and blood pressure remained normal during treatment. During the administration of MTX, three patients (9%) had CMV antigenemia; other infectious complications or nonhematological toxicities were not observed.
Side effects
Long time follow-up and survival
Up to 1 January 2010, the median follow-up time was 620 days (range, 229-882 days) from HSCT and 576 days (range, 192-852 days) from the onset of aGVHD. Among the 32 patients, 13 (40%) had bacterial infections, 9 (28%) had fungal infections and 21 (65%) had CMV infection, as identified by CMV antigenemia.
Of the 32 patients, 18 (56%) developed cGVHD, among whom 7 had limited disease. Leukemia relapse occurred in two (6%) patients, who eventually died from leukemia relapse. The 2-year cumulative incidence of relapse was 7%. Three patients (9%) died of TRM. The 2-year cumulative incidence of TRM was 11%. The causes of death were: relapse (n ¼ 2), infection (n ¼ 2) and hemorrhage (n ¼ 1). Cumulative incidences of relapse and TRM are shown in Figure 2 .
A total of 27 patients (84%) remain alive without leukemia relapse with a median survival of 682 days (range, 192-852 days) from the onset of aGVHD and 699 days (range, 229-882 days) from HSCT. The estimated survival at 2 years was 77%. The probability of survival is shown in Figure 3 .
Discussion
The current standard therapy for aGVHD is glucocorticoid MP (2 mg/kg/day), but this treatment still has drawbacks. First, systemic steroid therapy can result in increased blood glucose, increased blood pressure and infections. Second, treatment for aGVHD with glucocorticoid MP still has a low efficiency. VanLint et al. 7 reported that the early treatment of aGVHD with glucocorticoid MP at 10 mg/kg/ day did not improve the response rate as compared with 2 mg/kg/day (71 vs 68%; P ¼ 0.9), nor did it prevent evolution to aGVHD grades III-IV. CMV infections, TRM and survival rates were also comparable. The majority of patients with recurrent or continuous GVHD had greater steroid exposure and a higher risk of death. Moreover, there was a 2% incremental increase in the risk of death for every 1.0 mg/kg increase in cumulative MP exposure relative to the lowest dose (P ¼ 0 .045). Therefore, major efforts have been directed at new regimens that would reduce systemic steroid use. 3, 6, 16 Mielcarek et al. 4 reported that initial treatment with low-dose glucocorticoids (1 mg/ kg/day) for patients with grades I-II GVHD did not compromise disease control or mortality, and was associated with a decreased risk of invasive fungal infections and a shorter duration of hospitalization.
Recent studies have suggested that low doses of MTX, in addition to having an antimitotic effect, can induce a sustained suppression of T-cell activation, supporting its use in GVHD therapy. 17 The current pilot study was initiated to evaluate the safety and efficacy of MTX as a first-line treatment for aGVHD in a prospective clinical trial. The results showed that low-dose MTX (10 mg/day) combined with low doses of MP (0.5 mg/kg/day) were effective for aGVHD of varying severities and different involvement sites. No report of this combination regimen for the treatment of aGVHD has been found. In our recent report of low-dose MTX as a first-line therapy in patients with cGVHD, MTX treatment allowed for a significant reduction in the prednisone dosage (median 90%) from 20 (2.5-100) mg at the start of MTX administration to 5 (0-30) mg 1 month after MTX was last used. 10 This suggested that MTX and MP might have synergistic effects, a hypothesis that needed to be confirmed by in vitro and in vivo trials.
To our knowledge, there are three published reports evaluating the feasibility of low-dose MTX in the treatment of aGVHD, mostly as a salvage therapy, using a variety of assessments and definitions of responses. 9, 18, 19 Inagaki et al. 18 reported a response rate of 70% with MTX at a dose of 10 mg/m 2 weekly for a median of five doses for the treatment of aGVHD in children. de Lavallade et al. 19 found that 7 of 12 (58%) patients receiving MTX at a dose of 5 mg/m 2 weekly for a median of four infusions as a salvage treatment showed a response. These reports demonstrated the possible steroid-sparing effect of low-dose MTX for patients with steroid-refractory aGVHD; however, it remained difficult to judge the potential efficacy that this drug might have for the treatment of aGVHD at an earlier stage of the disease. Our earlier study included five cases with MTX as a first-line therapy for the treatment of aGVHD. 9 Our present study supports and confirms the efficacy of low-dose MTX combined with low-dose MP as a first-line therapy for the treatment of aGVHD.
In the current study, 18% of patients required secondline treatment and 56% of patients developed cGVHD. Mielcarek et al. 4 reported that 22% of patients received secondary therapy with an initial treatment of low-dose glucocorticoids (1 mg/kg/day) for aGVHD. VanLint et al. 7 reported that 26 of 34 (76%) evaluable patients developed cGVHD after MP (2 mg/kg/day) as a first-line therapy for aGVHD. Our results were comparable to those reports.
The rate of developing severe cytopenias during therapy seemed to be lower in this study than in previous reports, 9, 18 possibly because of the combination regime used in this study. MP might partly counteract cytopenias caused by MTX. Nevertheless, close monitoring of blood cell counts is necessary whenever MTX is administered. With decreased doses of MP, there is less effect on blood pressure and metabolism. In VanLint et al.'s 7 report, 15 and 5 of 47 patients developed hyperglycemia and hypertension, respectively, with MP (2 mg/kg/day). No other well-described adverse events, such as gastrointestinal symptoms, immune-mediated pneumonitis or renal impairment were seen even in our patients with long-term followup. Results from VanLint et al. 7 showed that after MP (2 mg/kg/day) as a first-line therapy for aGVHD, the occurrence of CMV antigenemia was 55%, 3-year actuarial TRM was 28%, relapse rates were 17% and the actuarial survival at 3 years was 63%. CMV antigenemia occurred in a similar proportion of patients in this study, especially considering that most of our patients received haploidentical HSCTs. Results of TRM, relapse and survival were not inferior to those found in that report. Low-dose and short-term use of MTX contributed to its safety. Therefore, these results confirmed that low-dose MTX combined with low-dose MP is safe and well tolerated.
In summary, our study showed that low-dose MTX combined with low-dose MP is an effective and safe treatment for aGVHD. Moreover, there may be synergistic effects between MTX and MP. The combination regimen may be eligible as an alternative form of first-line treatment for aGVHD, and it is especially preferable for those patients at a high risk of relapse. However, a randomized, controlled study is needed to compare the results of this new regimen with the standard therapy with MP (2 mg/kg/day).
